PF 6700841

Drug Profile

PF 6700841

Alternative Names: PF-06700841; PF6700841

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antipsoriatics
  • Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Plaque psoriasis; Ulcerative colitis
  • Discontinued Lupus vulgaris

Most Recent Events

  • 16 Aug 2017 Pfizer initiates enrolment in a phase I trial in healthy volunteers in Belgium (PO) (NCT03236493)
  • 04 Aug 2017 Pfizer plans a phase I trial in Healthy volunteers (NCT03236493)
  • 03 Mar 2017 Pharmacodynamics and efficacy data from a phase I trial in Plaque psoriasis presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top